Novacyt SA Valuation
| NVYTF Stock | USD 0.64 0.06 8.57% |
Novacyt SA is overvalued. Novacyt SA secures a last-minute Real Value of $0.59 per share. The latest price of the firm is $0.64. Our model forecasts the value of Novacyt SA from analyzing the firm fundamentals such as Return On Equity of -0.0198, profit margin of (0.1) %, and Current Valuation of (50.49 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Novacyt SA's price fluctuation is abnormally volatile at this time. Calculation of the real value of Novacyt SA is based on 3 months time horizon. Increasing Novacyt SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novacyt pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Novacyt SA. Since Novacyt SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novacyt Pink Sheet. However, Novacyt SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.64 | Real 0.59 | Hype 0.64 |
The real value of Novacyt Pink Sheet, also known as its intrinsic value, is the underlying worth of Novacyt SA Company, which is reflected in its stock price. It is based on Novacyt SA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Novacyt SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Novacyt SA helps investors to forecast how Novacyt pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novacyt SA more accurately as focusing exclusively on Novacyt SA's fundamentals will not take into account other important factors: Novacyt SA Total Value Analysis
Novacyt SA is now anticipated to have takeover price of (50.49 M) with market capitalization of 83.34 M, debt of 1.67 M, and cash on hands of 99.65 M. The negative valuation of Novacyt SA may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Novacyt SA fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(50.49 M) | 83.34 M | 1.67 M | 99.65 M |
Novacyt SA Investor Information
The company has price-to-book ratio of 0.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Novacyt SA recorded a loss per share of 0.17. The entity had not issued any dividends in recent years. The firm had 15:1 split on the 28th of June 2012. Based on the key measurements obtained from Novacyt SA's financial statements, Novacyt SA is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Novacyt SA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novacyt SA has an asset utilization ratio of 52.14 percent. This implies that the Company is making $0.52 for each dollar of assets. An increasing asset utilization means that Novacyt SA is more efficient with each dollar of assets it utilizes for everyday operations.Novacyt SA Ownership Allocation
Novacyt SA maintains a total of 70.63 Million outstanding shares. Novacyt SA secures 3.49 % of its outstanding shares held by insiders and 1.6 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Novacyt SA Profitability Analysis
The company reported the revenue of 95.78 M. Net Loss for the year was (9.73 M) with profit before overhead, payroll, taxes, and interest of 64.87 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novacyt SA's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novacyt SA and how it compares across the competition.
About Novacyt SA Valuation
The pink sheet valuation mechanism determines Novacyt SA's current worth on a weekly basis. Our valuation model uses a comparative analysis of Novacyt SA. We calculate exposure to Novacyt SA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novacyt SA's related companies.Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people.
8 Steps to conduct Novacyt SA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novacyt SA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novacyt SA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novacyt SA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novacyt SA's revenue streams: Identify Novacyt SA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novacyt SA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novacyt SA's growth potential: Evaluate Novacyt SA's management, business model, and growth potential.
- Determine Novacyt SA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novacyt SA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Novacyt SA Growth Indicators
Investing in growth stocks can be very risky. If the company such as Novacyt SA does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 70.6 M | |
| Quarterly Earnings Growth Y O Y | -0.971 | |
| Retained Earnings | 87.2 M |
Complementary Tools for Novacyt Pink Sheet analysis
When running Novacyt SA's price analysis, check to measure Novacyt SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt SA is operating at the current time. Most of Novacyt SA's value examination focuses on studying past and present price action to predict the probability of Novacyt SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt SA's price. Additionally, you may evaluate how the addition of Novacyt SA to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |